<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-61771</identifier>
<setSpec>0001-7310</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Cerebrotendunous Xanthomatosis: report of 4 patients</dc:title>
<dc:description xml:lang="en">Cerebrotendinous xanthomatosis (CTX) is an uncommon autosomal recessive disease caused by mutation of the CYP27A1 gene. It is characterized by the presence of xanthomas in different tissues, principally brain and tendon, due to the accumulation of  -cholestanol. Diagnosis is confirmed by measurement of serum -cholestanol and urinary bile alcohol levels. Therapy with chenodeoxycholic acid has been shown to be the most effective treatment and can halt progression of the disease. We present 4 patients with a history of neurological disorders since childhood and who were diagnosed with CTX after developing tendon xanthomas. Although diagnostic suspicion depends to a large extent on recognition of tendon xanthomas, these are not an early sign of the disease, which can present with neurological disorders, cataracts, and chronic diarrhea. Early diagnosis of CTX therefore rests on measurement of serum  -cholestanol levels, even in absence of tendon xanthomas (AU)</dc:description>
<dc:creator>Bodet, D</dc:creator>
<dc:creator>Girós, M</dc:creator>
<dc:creator>Heras, C</dc:creator>
<dc:creator>Bartralot, R</dc:creator>
<dc:creator>Bassas, P</dc:creator>
<dc:creator>García-Patos, V</dc:creator>
<dc:creator>Ferrándiz-Pulido, C</dc:creator>
<dc:creator>Savall, R</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">La xantomatosis cerebrotendinosa (XCT) es una enfermedad hereditaria infrecuente causada por la mutación del gen CYP27A1. Es característica la aparición de xantomas en diferentes tejidos, principalmente en el cerebro y los tendones, secundarios al depósito de  -colestanol. El diagnóstico se confirma mediante la determinación de  -colestanol en suero, y de los alcoholes biliares en orina. El ácido quenodesoxicólico es la terapia más eficaz, pudiendo llegar a frenar la progresión de la enfermedad. Presentamos 4 pacientes con alteraciones neurológicas desde la infancia que fueron diagnosticados de XCT tras el desarrollo de xantomas tendinosos. El reconocimiento de los xantomas tendinosos es fundamental para orientar el diagnóstico de XCT, pero estos no son un signo inicial de la enfermedad, que debuta con alteraciones neurológicas, cataratas o diarrea crónica. Por lo tanto, el diagnóstico temprano de la XCT requiere la determinación del  -colestanol sérico en estos pacientes, aun en ausencia de xantomas (AU)</dc:description>
<dc:source>Actas Dermosifiliogr;100(3): 222-226, abr. 2009. tab, ilus</dc:source>
<dc:identifier>ibc-61771</dc:identifier>
<dc:title xml:lang="es">Xantomatosis cerebrotendinosa: descripción de 4 casos</dc:title>
<dc:subject>^d331</dc:subject>
<dc:subject>^d32957^s22057</dc:subject>
<dc:subject>^d32957^s22033</dc:subject>
<dc:subject>^d32957^s22016</dc:subject>
<dc:subject>^d21012</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:subject>^d52519</dc:subject>
<dc:subject>^d9346^s22033</dc:subject>
<dc:subject>^d29229^s22033</dc:subject>
<dc:subject>^d14088</dc:subject>
<dc:subject>^d2681^s22073</dc:subject>
<dc:type>article</dc:type>
<dc:date>200904</dc:date>
</metadata>
</record>
</ibecs-document>
